FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

782371005: Galcanezumab (substance)


Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2019. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3753680011 Galcanezumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
3753681010 Galcanezumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
5589921000241117 galcanézumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Galcanezumab This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Calcitonin gene-related peptide receptor antagonist (disposition) true Inferred relationship Some
Galcanezumab Is a Monoclonal antibody true Inferred relationship Some
Galcanezumab Is a Substance with calcitonin gene-related peptide receptor antagonist mechanism of action (substance) true Inferred relationship Some

Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing only galcanezumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Galcanezumab Inferred relationship Some 1
Galcanezumab-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Galcanezumab Inferred relationship Some 1
Product containing galcanezumab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Galcanezumab Inferred relationship Some 1
Product containing only galcanezumab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Galcanezumab Inferred relationship Some 1
Galcanezumab 120 mg/mL solution for injection The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Galcanezumab Inferred relationship Some 1
Galcanezumab 120 mg/mL solution for injection This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Galcanezumab Inferred relationship Some 1

This concept is not in any reference sets

Back to Start